Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial

Jacobus Pfisterer, Florence Joly, Gunnar Kristensen, Joern Rau, Sven Mahner, Patricia Pautier, Ahmed El-Balat, Jean-Emmanuel Kurtz, Ulrich Canzler, Jalid Sehouli, Martin L Heubner, Andreas D Hartkopf, Klaus Baumann, Annette Hasenburg, Lars C Hanker, Antje Belau, Barbara Schmalfeldt, Dominik Denschlag, Tjoung-Won Park-Simon, Frédéric SelleChristian Jackisch, Alexander Burges, Hans-Joachim Lück, Günter Emons, Werner Meier, Martina Gropp-Meier, Willibald Schröder, Nikolaus de Gregorio, Felix Hilpert, Philipp Harter

Fingerprint

Dive into the research topics of 'Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences